STOCK TITAN

Eton Pharmaceuticals Stock Price, News & Analysis

ETON Nasdaq

Welcome to our dedicated page for Eton Pharmaceuticals news (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals stock.

ETON Pharmaceuticals (ETON) is a specialty pharmaceutical leader focused on rare disease treatments through innovative FDA pathways. This page aggregates all verified company announcements, regulatory updates, and therapeutic developments.

Access real-time updates on ETON's 505(b)(2) pipeline progress, pediatric endocrinology treatments, and strategic partnerships. Investors and healthcare professionals will find essential information on:

- FDA approval milestones
- Clinical trial results
- Intellectual property updates
- Commercialization partnerships
- Financial performance highlights

Bookmark this page for streamlined tracking of ETON's advancements in metabolic disorder treatments and rare disease therapies. Our curated news collection supports informed decision-making for stakeholders across the healthcare ecosystem.

Rhea-AI Summary

Eton Pharmaceuticals (ETON) reported its financial results for Q4 and full year 2020, revealing a significant net loss of $28.0 million, up from $18.3 million in 2019. The company's revenue was $0.1 million for Q4 2020, largely due to the late launch of ALKINDI SPRINKLE. Notable milestones included the launch of ALKINDI SPRINKLE and Alaway Preservative-Free, with an expectation of over $25 million in revenue for 2021. Eton completed a sale of its neurology portfolio for up to $45 million, enhancing its profitability outlook. However, ongoing high R&D and SG&A expenses remain concerning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
-
Rhea-AI Summary

Eton Pharmaceuticals, Inc (Nasdaq: ETON) will announce its fourth quarter and full year 2020 financial results on March 16, 2021, at 4:30 p.m. ET. Management will host a conference call and audio webcast to discuss these outcomes and provide a business update. Interested parties can access the live webcast on Eton's investor section of its website. Eton focuses on developing innovative treatments for rare pediatric diseases and currently has three FDA-approved products and six additional products submitted for FDA review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a company dedicated to innovative treatments for rare pediatric diseases, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference from February 24-26, 2021. Eton currently has three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products submitted to the FDA. The company emphasized that forward-looking statements regarding its business strategy and product development may be subject to risks and uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
Rhea-AI Summary

Eton Pharmaceuticals announced the sale of its neurology portfolio to Azurity Pharmaceuticals for up to $45 million, plus royalties on sales. The portfolio includes drug candidates ET-105, ET-104, and ET-101, which are under FDA review. CEO Sean Brynjelsen highlighted that this deal allows Eton to concentrate on its orphan drug business and improve profitability by avoiding sales force investments. Eton will receive $15 million at closing, with additional payments tied to regulatory and sales milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) has announced the acquisition of Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc. This product is crucial for treating Adrenocortical Insufficiency in children under 17. Following its positive reception in the U.S., Eton aims to expand into the Canadian market, addressing significant unmet needs among pediatric patients. The acquisition reflects Eton's commitment to becoming a leader in orphan drug development, as noted by both Eton and Diurnal executives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
-
Rhea-AI Summary

Eton Pharmaceuticals has received FDA acceptance for its new drug application (NDA) for topiramate oral solution, targeting pediatric and adolescent patients. The application, which includes three indications for seizures and migraine prevention, has a PDUFA date of August 6, 2021. This marks a significant step for Eton, which has three neurology-focused oral liquid products submitted to the FDA, all slated for approval in 2021. The company currently has three FDA-approved products and aims to develop treatments for rare pediatric diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announces the exclusive availability of ALKINDI® SPRINKLE through AnovoRx Specialty Pharmacy. This FDA-approved treatment is designed for pediatric patients with Adrenocortical Insufficiency (AI), and provides dosing flexibility with strengths of 0.5 mg to 5 mg. The Eton Cares Program will assist patients in accessing this medication. Eton estimates that AI affects between 5,000 and 11,000 children in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) reported Q3 2020 financial results, revealing a revenue of ($0.2) million, attributed to a price reduction of Biorphen. SG&A expenses rose to $3.4 million, while R&D expenses decreased to $2.8 million. The net loss increased to $6.5 million compared to $5.0 million a year ago. Eton successfully closed an oversubscribed equity offering raising approximately $22.5 million. Key milestones include the FDA approval of ALKINDI SPRINKLE, expected to launch by November, and four NDAs submitted with upcoming PDUFA dates in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Summary

Eton Pharmaceuticals (ETON) announced it will release its third quarter 2020 financial and operational results on November 12, 2020. A conference call to discuss these results and provide a business update is scheduled for 4:30 p.m. ET. The call can be accessed domestically at 1-866-795-8473 and internationally at 1-470-495-9161. Eton specializes in innovative treatments for rare pediatric diseases and has three FDA-approved products, with six additional products in late-stage development, five of which are submitted to the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences earnings
Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) has successfully closed an offering of 3,220,000 shares of common stock at $7.00 per share, raising approximately $22.5 million before expenses. This total includes 420,000 shares from the underwriter's overallotment option. The net proceeds are earmarked for general corporate purposes such as research and development, capital expenditures, and working capital needs. National Securities Corporation managed the offering. Please refer to the SEC for the final prospectus details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags

FAQ

What is the current stock price of Eton Pharmaceuticals (ETON)?

The current stock price of Eton Pharmaceuticals (ETON) is $14.45 as of July 3, 2025.

What is the market cap of Eton Pharmaceuticals (ETON)?

The market cap of Eton Pharmaceuticals (ETON) is approximately 374.4M.
Eton Pharmaceuticals

Nasdaq:ETON

ETON Rankings

ETON Stock Data

374.37M
25.66M
5.57%
49.37%
1.11%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
DEER PARK